Skip to Main Content

Advertisement

Skip Nav Destination

Abstract LB-151: The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity in combination with bevacizumab

Cancer Res (2017) 77 (13_Supplement): LB-151.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Markus Joerger
  • Thomas Hundsberger
  • Simon Haefliger
  • Roger von Moos
  • Andreas F. Hottinger
  • Thomas Kaindl
  • Marc Engelhardt
  • Michalina Marszewska
  • Heidi Lane
  • Patrick Roth
  • Anastasios Stathis
Investigational New Drugs (2023) 41 (2): 267.
  • Markus Joerger
  • Anastasios Stathis
  • Yannis Metaxas
  • Dagmar Hess
  • Mara Mantiero
  • Michael Mark
  • Matthias Volden
  • Thomas Kaindl
  • Marc Engelhardt
  • Patrice Larger
  • Heidi Lane
  • Peter Hafner
  • Nicole Levy
  • Silvia Stuedeli
  • Cristiana Sessa
  • Roger von Moos
Investigational New Drugs (2020) 38 (4): 1067.
  • Rebecca Kristeleit
  • Jeffry Evans
  • L. Rhoda Molife
  • Nina Tunariu
  • Heather Shaw
  • Sarah Slater
  • Noor R. Md Haris
  • Nicholas F. Brown
  • Martin D. Forster
  • Nikolaos Diamantis
  • Robert Rulach
  • Alastair Greystoke
  • Uzma Asghar
  • Mihaela Rata
  • Stephanie Anderson
  • Felix Bachmann
  • Alison Hannah
  • Thomas Kaindl
  • Heidi A. Lane
  • Patrice J. Larger
  • Anne Schmitt-Hoffmann
  • Marc Engelhardt
  • Alexandar Tzankov
  • Ruth Plummer
  • Juanita Lopez
British Journal of Cancer (2020) 123 (9): 1360.
Close Modal

or Create an Account

Close Modal
Close Modal